. All translation elongation inhibitors 146 (anisomycin, cycloheximide, homoharringtonine, lactimidomycin, and nagilactone C) also strongly inhibited 147 both S35 incorporation and PfIVT (Fig 2) . Cycloheximide was additionally tested at 1000-fold its EC50, as it 148 did not inhibit S35 incorporation at the lower concentrations tested, but did at this higher concentration, in line 149 with inhibitory concentrations in recent reports, which also show that significantly higher concentrations of 150 cycloheximide are required for complete, measurable inhibition of translation than for rapid and total parasite 151 killing in vivo (S1 Fig) [8, 9, 35] . Suramin, which has been shown to inhibit both translation initiation and 152 elongation, robustly inhibited PfIVT, but not S35 incorporation, likely due to poor cell permeability and the 153 short timeframe of the S35 assay (2 hour drug pre-incubation followed by 2 hour radiolabel incorporation) 154 ( Fig 2) . The tRNA mimetic puromycin, which induces premature termination of nascent polypeptides, 155 inhibited both S35 incorporation and PfIVT with similar efficacy (Fig 2) . Elucidating an even greater range of 156 utility for the PfIVT assay, we found it to be capable of identifying inhibitors of non-ribosomal components of 157 translation. The glutamyl-prolyl-tRNA synthetase inhibitor halofuginone inhibits both S35 incorporation and 158 the PfIVT assay ( Fig 2) . In sum, these data demonstrate the ability of the PfIVT assay to interrogate both 159 direct ribosomal activity, as well as extra-ribosomal components of the translational machinery.
160 Importantly, all of the eukaryotic ribosome-specific inhibitors, which therefore should inhibit only P.
166 falciparum cytoplasmic and not apicoplast or mitochondrial ribosomes, displayed inhibition in the PfIVT 167 assay, with several achieving complete or near complete blocking of translation (suramin, anisomycin, 168 lactimidomycin, nagilactone C) ( Fig 2) . In addition, the prokaryotic ribosome-specific inhibitor thiostrepton 169 did not inhibit the PfIVT assay at any concentration tested, despite inhibiting the S35 assay at concentrations 170 above its determined EC50 (Fig 3) . Thiostrepton is known to have multiple targets apart from ribosomes in 171 eukaryotes and has been shown to induce an ER stress response with a phenotype similar to thapsigargin, 172 which likely accounts for its activity in the S35 assay [36] [37] [38] . 
235
The PfIVT assay is particularly valuable to the study of P. falciparum translation as a direct measure of 236 translation, as opposed to the indirect measures to which the field has historically been constrained, such as 237 incorporation of radiolabeled amino acids in vivo. Importantly, our data show the PfIVT assay is significantly 238 more specific, and in some cases more sensitive, than S35-radiolabel incorporation in identifying small 239 molecule inhibitors of translation. Indeed, the PfIVT assay specifically identified all eukaryotic translation 240 inhibitors tested, while S35-radiolabel incorporation was prone to false-positives. We found that none of the 241 clinically approved antimalarials tested are inhibitors of translation, emphasizing the potential for translation 242 as a useful therapeutic target, as there is unlikely to be pre-existing mechanism-specific resistance to any 243 identified candidates resulting from use of these drugs. It is notable that mefloquine, in contrast to other 244 previously reported translation inhibitors, did not exhibit any inhibitory activity. Mefloquine was likely 13 245 mischaracterized as an 80S ribosome inhibitor through a combination of non-specific inhibition of S35 246 incorporation, as well as artifacts arising from cryo-EM structures obtained under the non-physiologic 247 condition of 10mM magnesium -well above the ~4mM magnesium that we have found to be optimal for 248 translation (Fig 1)[9] .
249
While the PfIVT assay exhibits clear benefits over existing methodologies for the study of P.
250 falciparum translation, we acknowledge that the technique has several limitations. As is the case with in vitro 251 translation systems in other organisms, the current assay is likely biased toward the study of non-cap-252 dependent initiation and elongation. We utilized uncapped mRNA in this study to focus specifically on 253 activity of the 80S ribosome itself, rather than the cap-recognition apparatus. It is possible that utilization of 254 capped mRNA in future studies would facilitate interrogation of cap-dependent translation initiation.
255 Likewise, there are few characterized pharmacologic inhibitors of eukaryotic translation termination, none of 256 which are currently commercially available; thus, the PfIVT system, as described, may not be sensitive to all 257 specific inhibitors of translation termination. Additionally, some translation inhibitors, such as 258 homoharringtonine, demonstrated greater potency in the S35 incorporation and growth inhibition assays than 259 in PfIVT. Such variation between the two assays may suggest off-target effects of these drugs, or differences 260 between whole living cells and cellular extracts.
261
Determining the true molecular targets of antimalarials is critical to improved therapeutic 262 development. Exploiting differences between P. falciparum and mammalian ribosomes remains a promising 263 avenue, as evidenced by the potent and discriminating drug DDD107498. Here, we have shown that 264 orthogonal biochemical assays may be used to test hypotheses generated by structural data and cell-based 265 assessments. Our investigation of mefloquine reaffirms that direct functional measurements of drug activity 266 are critical to identifying the genuine molecular targets of drugs. Importantly, we show that the PfIVT assay is 267 a uniquely direct measure of P. falciparum translation that can be used to facilitate a better understanding of 14 268 the specifics of P. falciparum protein synthesis, with potentially great consequences for antimalarial 269 therapeutic development. 
